Cost-effectiveness of an online homemonitoring program in idiopathic pulmonary fibrosis

被引：0
|
作者：
Moor, Catharina [1 ]
Kimman, M. L. [2 ]
Mostard, R. L. M. [3 ]
Grutters, J. C. [4 ]
Bresser, P. [5 ]
Aerts, J. G. J. V. [1 ]
Wijsenbeek, M. S. [1 ]
机构：
[1] Erasmus MC, Dept Resp Med, Rotterdam, Netherlands
[2] MUMC, Dept Hlth Technol Assessment, Maastricht, Netherlands
[3] Zuyderland MC, Dept Resp Med, Heerlen, Netherlands
[4] St Antonius Hosp, Dept Resp Med, Nieuwegein, Netherlands
[5] OLVG, Dept Resp Med, Amsterdam, Netherlands
来源：
EUROPEAN RESPIRATORY JOURNAL | 2021年 / 58卷
关键词：
Idiopathic pulmonary fibrosis; Telemedicine; Monitoring;
D O I：
10.1183/13993003.congress-2021.PA397
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA397
引用
收藏
页数：2
相关论文
共 50 条
  • [1] NINTEDANIB COST-EFFECTIVENESS IN IDIOPATHIC PULMONARY FIBROSIS IN THE UK
    Rinciog, C.
    Watkins, M.
    Chang, S.
    Maher, T.
    LeReun, C.
    Esser, D.
    Diamantopoulos, A.
    VALUE IN HEALTH, 2016, 19 (07) : A553 - A553
  • [2] A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
    Rinciog, C.
    Watkins, M.
    Chang, S.
    Maher, T. M.
    LeReun, C.
    Esser, D.
    Diamantopoulos, A.
    PHARMACOECONOMICS, 2017, 35 (04) : 479 - 491
  • [3] A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
    C. Rinciog
    M. Watkins
    S. Chang
    T. M. Maher
    C. LeReun
    D. Esser
    A. Diamantopoulos
    PharmacoEconomics, 2017, 35 : 479 - 491
  • [4] SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF MEDICINES FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
    Soulard, S.
    Wammes, K.
    Picavet, E.
    Munack, U.
    Druez, C.
    VALUE IN HEALTH, 2017, 20 (09) : A555 - A555
  • [5] Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
    C. Rinciog
    A. Diamantopoulos
    A. Gentilini
    B. Bondue
    C. Dahlqvist
    A. Froidure
    W. A. Wuyts
    S. Soulard
    PharmacoEconomics - Open, 2020, 4 : 449 - 458
  • [6] COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE VERSUS NINTEDANIB ON THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
    Ho, R.
    Rufino, C.
    Lisondo, C.
    Alves, M.
    VALUE IN HEALTH, 2017, 20 (09) : A893 - A894
  • [7] Cost-Effectiveness of Common Therapies in Idiopathic Pulmonary Fibrosis: A Discrete Event Simulation
    Strand, L.
    Canestaro, W.
    Steuten, L.
    Raghu, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [8] Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
    Rinciog, C.
    Diamantopoulos, A.
    Gentilini, A.
    Bondue, B.
    Dahlqvist, C.
    Froidure, A.
    Wuyts, W. A.
    Soulard, S.
    PHARMACOECONOMICS-OPEN, 2020, 4 (03) : 449 - 458
  • [9] Cost-effectiveness of novel diagnostic tools for idiopathic pulmonary fibrosis in the United States
    Christopher J. Cadham
    Joshua Reicher
    Michael Muelly
    David W. Hutton
    BMC Health Services Research, 25 (1)
  • [10] The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation
    不详
    HEALTH TECHNOLOGY ASSESSMENT, 2015, 19 (20) : 1 - +
12345